Covid-19 controversies: the tocilizumab chapter
- PMID: 33504502
- DOI: 10.1136/bmj.n244
Covid-19 controversies: the tocilizumab chapter
Conflict of interest statement
Competing interest: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: EM carries out advisory board work on antibiotics for Shionogi, Summit, Entasis, Merck, and AbbVie and is a site investigator for REMAP-CAP in the US (site did not enroll to interleukin 6ra domain). The BMJ policy on financial interests is here: https://www.bmj.com/sites/default/files/attachments/resources/2016/03/16-current-bmj-education-coi-form.pdf.
Comment on
-
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84. BMJ. 2021. PMID: 33472855 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical